Prokidney’s REACT Study: A Promising Step in Diabetes and Kidney Disease Treatment

Prokidney Corp. ((PROK)) announced an update on their ongoing clinical study.

Prokidney Corp. is conducting a study titled ‘A Phase 2, Randomized, Open-Labeled, Repeat Dose, Safety and Efficacy Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)’. The study aims to evaluate the safety, efficacy, and durability of REACT injections on renal function in patients with diabetes and chronic kidney disease. This research is significant as it could lead to improved treatment options for these conditions.

The intervention being tested is the Renal Autologous Cell Therapy (REACT), a biological treatment involving autologous selected renal cells. The therapy is designed to enhance renal function by delivering these cells percutaneously into the kidneys.

This Phase 2 study is interventional, with a randomized allocation and a parallel intervention model. There is no masking involved, and the primary purpose is treatment. The study involves two cohorts receiving different dosing schedules of REACT injections.

The study commenced on July 27, 2021, with an actual start date. The primary completion date and estimated study completion date are not specified, but the last update was submitted on June 24, 2025. These dates are crucial for tracking the study’s progress and anticipating results.

This study update could positively impact Prokidney’s stock performance and investor sentiment, as successful results might enhance the company’s market position in renal therapies. The industry context includes competition from other firms developing innovative treatments for diabetes and chronic kidney disease.

The study is ongoing, with further details available on the ClinicalTrials portal.